Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.71 +0.19 (+1.03%)
Delayed Quote Updated: 1:49 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Preview: Takeda Pharmaceutical's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For January 30, 2025 ↗
 
Via Benzinga
News headline image
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights ↗
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal. 
Via Benzinga
News headline image
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch ↗
The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027. 
Via Benzinga
News headline image
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency ↗
Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option. 
Via Benzinga
News headline image
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst ↗
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
News headline image
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients ↗
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease. 
Via Benzinga
News headline image
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump ↗
Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules... 
Via Benzinga
Topics Climate Change
News headline image
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
News headline image
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization ↗
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... 
Via Benzinga
News headline image
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
Via MarketBeat
Topics Economy
News headline image
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.